CompletedPhase 1

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

United States64 participantsStarted 2022-03-09

Plain-language summary

This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Type 1 DM and/or insulin-dependent type 2 diabetes mellitus (T2DM), or uncontrolled T2DM requiring rescue therapy in study ALT-801-105
✕. History of pancreatitis or hypersensitivity reaction to GLP-1 analogues

What they're measuring

The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)

Timeframe: Up to Day 110

Trial details

NCT IDNCT05292911

SponsorAltimmune, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-10-31

View on ClinicalTrials.gov More Non-Alcoholic Fatty Liver Disease trials